February 13th, 2008
Eurofins’ consolidated Group revenues for the year ended 31 December 2007 were EUR 491.8m (2006 EUR 368.0m), representing growth of 34% and ahead of the last guidance of EUR 460m given at the beginning of November*. Organic growth for the year was over 10%. Revenues have therefore again more than doubled in two years, from EUR 233.1m in 2005 to EUR 491.8m in 2007. In the 4th quarter significant time and resource was dedicated to the acquisition and early stages of integration of Analycen and Operon**.
The breakdown by region is as follows:
2007 (EUR m)
Benelux 40.9 British Isles 49.5 France 98.6 Germany 101.9 North America 61.1 Scandinavia 88.7 Other 51.1 Total 491.8
Benelux 8.3 British Isles 10.1 France 20.0 Germany 20.7 North America 12.4 Scandinavia 18.0 Other 10.4 Total 100%
The Group will publish its full annual results for 2007 on the 5th March 2008. Presentations will be given by management on that day in both Paris and Frankfurt.
- c.f. press release 7 November 2007
- c.f. press releases of 3 October and 22 November respectively
For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: firstname.lastname@example.org
Notes for the editor:
Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
Information réglementée :
Communiqués au titre de l'obligation d'information permanente
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIF||Euronext Paris||419.65 (c)||0.00%||0|